CND Life Sciences

Executive Summary

CND Life Sciences is a commercial-stage neurodiagnostics company that has developed and commercialized the Syn-One Test, a minimally invasive skin biopsy test detecting abnormal phosphorylated alpha-synuclein to aid in diagnosing Parkinson's disease and related synucleinopathies. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, the company provides this diagnostic service to clinicians and patients. The Syn-One Test addresses a significant unmet need for objective biomarkers in neurodegenerative diseases, where diagnosis historically relies on clinical assessment. CND Life Sciences is positioned to capture market share as awareness of alpha-synuclein testing grows, particularly among movement disorder specialists. The company's commercial-stage status and regulatory compliance provide a foundation for scaling operations, though adoption remains moderate, limited by reimbursement coverage and physician education. With no disclosed funding rounds or valuation, the financial profile is opaque, but the niche focus and proprietary technology offer a differentiated investment thesis in neurology diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Medicare and private payer coverage for Syn-One Test70% success
• Q4 2026Publication of new clinical validation data in peer-reviewed journals80% success
• Q2 2026Strategic partnership with a larger diagnostics or pharmaceutical company40% success